BTIG analyst Dane Leone initiated MacroGenics wiht a Buy rating and $35 price target. The analyst views MacroGenics' valuation as attractive given the substantial discount of the current enterprise value when compared to the potential payments from multiple partnerships across the DART platform. Enoblituzumab Phase I data expected in late 2016 should help bridge news flow into Margetuximab updates during 1H 2017, and net present value analysis of current clinical programs could significantly increase as the B7-H3 data warrants incorporation of Enoblituzumab and/or MGD009.

B. Riley initiated coverage of MacroGenics with a Buy rating and $25 price target. The analyst views the company's most advanced candidate, vobra duo, as "significantly de-risked" in the ongoing over-enrolled Phase II TAMARACK registration-enabling study, the analyst tells investors in a research note. The firm MacroGenics' fully integrated development and manufacturing capabilities have led to a partnered program portfolio consisting of three FDA-approved medicines and earlier-stage pipeline candidates.

B. Riley initiated coverage of MacroGenics with a Buy rating and $25 price target.